Hollander PA, et al. - In this phase 3, randomized, active-controlled, open-label, 24-week clinical trial, the researchers compared the efficacy and safety of MK-1293 insulin glargine (Mk-Gla) and Lantus (Sa-Gla) in people with type 2 diabetes mellitus (T2DM). Five hundred thirty-one participants with T2DM (HbA1c ≤11.0%) either eligible for or currently taking basal insulin (≥10 U/day) were recruited. In people with T2DM, Mk-Gla and Sa-Gla showed similar efficacy and safety over 24 weeks of treatment.